Normalization in hemophilia: conceptual foundations and clinical implications

Hemophilia is an inherited bleeding disorder characterized by a deficiency in clotting factor, leading to impaired thrombin generation, bleeding complications, and long-term morbidity that severely impacts patients’ quality of life. Recent advancements in treatment have significantly empowered the hemophilia community, improving disease control, reducing treatment burden, expanding access to care, and lowering the risks of lifelong complications. These advancements have continually elevated the goals of hemophilia care. The latest innovations have introduced a new ambition: the “normalization” of life for persons with hemophilia. This aspiration is both desirable and promising, with the potential to greatly enhance patients’ quality of life and achieve equitable health outcomes. However, it is crucial for the entire community to first determine and define what constitutes an optimal and realistically achievable level of hemostasis normalization using current and emerging therapies. The significant psychosocial impact of hemophilia underscores the importance of targeting not only hemostasis normalization but also life normalization. This approach prioritizes reducing treatment burden and restoring mental well-being. Novel standardized tools are urgently needed to appropriately complement novel therapies, as traditional bleeding rate-based outcome metrics are becoming inadequate for assessing treatment superiority objectively. The potential risks of striving for normalized hemostasis must also be carefully considered. Moreover, specific needs and challenges associated with normalization must be addressed, particularly for carriers and women and girls with hemophilia.